The HER2 heterodimerization inhibitor pertuzumab is active against colon cancer cells in vitro and in vivo
N Andre, A Schoeneck, I Schwarte-Waldhoff, M Hasmann, W Schmiegel, A Reinacher-Schick · Zeitschrift für Gastroenterologie · 2006 · Heft 04
Bibliografische Angaben
Zusammenfassung
Aims: 60–80% of all colon cancers show an upregulation of HER1/EGFR while their HER2-expression is variable and ranges from 20% in early stages up to 80% in metastatic disease. Both HER1/EGFR and HER2 overexpression may be associated with poor prognosis. Pertuzumab is a new antibody targeting HER2 and the first member of the new class of HER-dimerization inhibitors (HDI) which inhibit ligand dependent and independent cell proliferation. So far, some antibody effect has been shown in lung and breast cancer xenografts. Efficacy of pertuzumab against colon cancer is unknown. Aim: To investigate the effect of pertuz…
